利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

6 条记录 (耗时 0.023 秒)

    Interferon β variants and conjugates
    4.
    发明授权
    Interferon β variants and conjugates 失效
    干扰素β变体和缀合物

    公开(公告)号：US07144574B2

    公开(公告)日：2006-12-05

    申请号：US10084706

    申请日：2002-02-26

    申请人： Poul Baad Rasmussen ,  Grethe Rasmussen ,  Kim Vilbour Andersen ,  Claus Bornaes

    发明人： Poul Baad Rasmussen ,  Grethe Rasmussen ,  Kim Vilbour Andersen ,  Claus Bornaes

    IPC分类号： A61K38/21 ,  A61K88/00 ,  C07K17/00

    CPC分类号： B82Y5/00 ,  A61K9/0019 ,  A61K31/724 ,  A61K38/21 ,  A61K38/215 ,  A61K47/40 ,  A61K47/6951 ,  C07K14/565 ,  A61K2300/00

    摘要： The invention relates to a conjugate exhibiting interferon β (IFNB) activity and comprising at least one first non-polypeptide moiety covalently attached to an IFNB polypeptide, the amino acid sequence of which differs from that of wildtype human IFNB in at least one introduced and at least one removed amino acid residue comprising an attachment group for said first non-polypeptide moiety. The first non-polypeptide moiety is e.g. a polymer molecule or a sugar moiety. The conjugate finds particular use in therapy. The invention also relates to a glycosylated variant of a parent IFNB polypeptide comprising at least one in vivo glycosylation site, wherein an amino acid residue of said parent polypeptide located close to said glycosylation site has been modified to obtain the variant polypeptide having an increased glycosylation as compared to the glycosylation of the parent polypeptide.

    摘要翻译： 本发明涉及一种表现出干扰素β（IFNB）活性的缀合物，其包含共价连接到IFNB多肽的至少一个第一非多肽部分，所述第一非多肽部分与至少一个引入的和在 至少一个除去的氨基酸残基，其包含所述第一非多肽部分的连接基团。 第一非多肽部分是例如。 聚合物分子或糖部分。 该缀合物在治疗中特别有用。 本发明还涉及包含至少一个体内糖基化位点的母体IFNB多肽的糖基化变体，其中位于所述糖基化位点附近的所述亲本多肽的氨基酸残基已被修饰以获得具有增加的糖基化的变体多肽作为 与母体多肽的糖基化相比。

    Interferon beta-like molecules
    5.
    发明授权
    Interferon beta-like molecules 失效
    干扰素β样分子

    公开(公告)号：US07431921B2

    公开(公告)日：2008-10-07

    申请号：US10609296

    申请日：2003-06-27

    申请人： Poul Baad Rasmussen ,  Grethe Rasmussen ,  Kim Vilbour Andersen ,  Claus Bornaes

    发明人： Poul Baad Rasmussen ,  Grethe Rasmussen ,  Kim Vilbour Andersen ,  Claus Bornaes

    IPC分类号： A61K38/21 ,  C07K17/00

    CPC分类号： A61K9/0019 ,  A61K9/0073 ,  A61K31/724 ,  A61K38/21 ,  A61K38/215 ,  A61K47/40 ,  A61K47/60 ,  A61K47/6951 ,  B82Y5/00 ,  C07K14/565 ,  A61K2300/00

    摘要： The invention relates to a conjugate exhibiting interferon β (IFNB) activity and comprising at least one first non-polypeptide moiety covalently attached to an IFNB polypeptide, the amino acid sequence of which differs from that of wildtype human IFNB in at least one introduced and at least one removed amino acid residue comprising an attachment group for said first non-polypeptide moiety. The first non-polypeptide moiety is e.g. a polymer molecule or a sugar moiety. The conjugate finds particular use in therapy. The invention also relates to a glycosylated variant of a parent IFNB polypeptide comprising at least one in vivo glycosylation site, wherein an amino acid residue of said parent polypeptide located close to said glycosylation site has been modified to obtain the variant polypeptide having an increased glycosylation as compared to the glycosylation of the parent polypeptide.

    摘要翻译： 本发明涉及一种表现出干扰素β（IFNB）活性的缀合物，其包含共价连接到IFNB多肽的至少一个第一非多肽部分，所述第一非多肽部分与至少一个引入的和在 至少一个除去的氨基酸残基，其包含所述第一非多肽部分的连接基团。 第一非多肽部分是例如。 聚合物分子或糖部分。 该缀合物在治疗中特别有用。 本发明还涉及包含至少一个体内糖基化位点的母体IFNB多肽的糖基化变体，其中位于所述糖基化位点附近的所述亲本多肽的氨基酸残基已被修饰以获得具有增加的糖基化的变体多肽作为 与母体多肽的糖基化相比。

    Pharmaceutical composition
    6.
    发明授权
    Pharmaceutical composition 失效
    药物组成

    公开(公告)号：US5939390A

    公开(公告)日：1999-08-17

    申请号：US925708

    申请日：1997-09-09

    申请人： Hans Flodgaard ,  Poul Baad Rasmussen

    发明人： Hans Flodgaard ,  Poul Baad Rasmussen

    IPC分类号： A61K38/00 ,  A61K47/48 ,  C07K14/47

    CPC分类号： A61K47/48023 ,  A61K47/48046 ,  C07K14/4723 ,  A61K38/00 ,  Y10S530/829

    摘要： The present invention relates to a pharmaceutical composition for the prevention or treatment of diseases or conditions involving stress injury to cells, the composition comprising(a) a lipid-containing substance having a lipid portion which is structurally identical with or analogous to a ceramide, conjugated to(b) a protein capable of binding said lipid-containing substance in such a way that, when the conjugate is contacted with living cells, the lipid-containing substance activates a ceramide-activated protein phosphatase resulting in down-regulation of cellular metabolism, and(c) a pharmaceutically acceptable diluent or carrier.

    摘要翻译： 本发明涉及用于预防或治疗涉及对细胞的应激损伤的疾病或病症的药物组合物，该组合物包含（a）具有与神经酰胺结构相似或相似的脂质部分的含脂物质， 至（b）能够结合所述含脂物质的蛋白质，使得当缀合物与活细胞接触时，含脂物质激活神经酰胺活化蛋白磷酸酶，导致细胞代谢的下调， 和（c）药学上可接受的稀释剂或载体。